Literature DB >> 30904494

Structural insights on druggable hotspots in CD147: A bull's eye view.

Dhivya Kumar1, Umashankar Vetrivel2, Sowmya Parameswaran3, Krishna Kumar Subramanian4.   

Abstract

CD147/Basigin/EMMPRIN (Extracellular Matrix Metalloproteinase inducer) is a single pass type1 transmembrane protein playing a central role in developmental process, wound healing, nutrient transport, inflammation, arthritis and also in microbial pathologies. It is also found to be a potent stimulator of MMP (matrix metalloproteinases) and has been considered as a prognostic marker in cancer. Dysregulation of CD147 is reported in several types of cancer. It activates cell proliferation, invasion, metastasis and inhibits tumor cell apoptosis under hypoxic condition. Thus, CD147 serves as a hub protein in cancer, as it is involved in several homophilic and heterophilic cellular interactions spanning the major hallmarks of cancer. Targeting these interactions is considered to be an efficient therapeutic modality in cancerous conditions. Hence, by this review we intend to collate the structure-function relationships of CD147, with an exclusive thrust on potential druggable hotspots based on its intra and inter molecular interactions.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  CD147; Drug design; EMMPRIN; Hotspots

Mesh:

Substances:

Year:  2019        PMID: 30904494     DOI: 10.1016/j.lfs.2019.03.044

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  9 in total

Review 1.  Matrix Metalloproteinases and Their Inhibitors in Pulmonary Fibrosis: EMMPRIN/CD147 Comes into Play.

Authors:  Lourdes Chuliá-Peris; Cristina Carreres-Rey; Marta Gabasa; Jordi Alcaraz; Julián Carretero; Javier Pereda
Journal:  Int J Mol Sci       Date:  2022-06-21       Impact factor: 6.208

Review 2.  Monocarboxylate transporters in cancer.

Authors:  Valéry L Payen; Erica Mina; Vincent F Van Hée; Paolo E Porporato; Pierre Sonveaux
Journal:  Mol Metab       Date:  2019-07-27       Impact factor: 7.422

Review 3.  SARS-CoV-2 Immuno-Pathogenesis and Potential for Diverse Vaccines and Therapies: Opportunities and Challenges.

Authors:  Andrew R McGill; Roukiah Kahlil; Rinku Dutta; Ryan Green; Mark Howell; Subhra Mohapatra; Shyam S Mohapatra
Journal:  Infect Dis Rep       Date:  2021-02-04

4.  The CD147 Protein Complex Is Involved in Entry of Chikungunya Virus and Related Alphaviruses in Human Cells.

Authors:  Lien De Caluwé; Sandra Coppens; Katleen Vereecken; Simon Daled; Maarten Dhaenens; Xaveer Van Ostade; Dieter Deforce; Kevin K Ariën; Koen Bartholomeeusen
Journal:  Front Microbiol       Date:  2021-02-25       Impact factor: 5.640

5.  Computational Modeling of T Cell Hypersensitivity during Coronavirus Infections Leading to Autoimmunity and Lethality.

Authors:  Alper Tunga Celebi; Goksu Uzel; Ece Oylumlu; Cengiz Baykasoglu; Ata Mugan; Sophie Joly; Ceren Ciraci
Journal:  Comput Math Methods Med       Date:  2022-03-22       Impact factor: 2.238

Review 6.  Role of MMP-2 and CD147 in kidney fibrosis.

Authors:  Zhengyuan Cheng; Xiaojuan Zhang; Yu Zhang; Li Li; Pingsheng Chen
Journal:  Open Life Sci       Date:  2022-09-14       Impact factor: 1.311

7.  Immunohistochemical basigin expression level in thyroid cancer tissues.

Authors:  Wan-Ping Guo; Deng Tang; Yu-Yan Pang; Xiao-Jiao Li; Gang Chen; Zhi-Guang Huang; Xiao-Zhun Tang; Qin-Qiao Lai; Jin-Yan Gan; Xiao-Li Huang; Xiao-Fan Liu; Zhi-Xiao Wei; Wei Ma
Journal:  World J Surg Oncol       Date:  2020-09-05       Impact factor: 2.754

8.  Differential Modulation of Matrix Metalloproteinases-2 and -7 in LAM/TSC Cells.

Authors:  Silvia Ancona; Emanuela Orpianesi; Clara Bernardelli; Eloisa Chiaramonte; Raffaella Chiaramonte; Silvia Terraneo; Fabiano Di Marco; Elena Lesma
Journal:  Biomedicines       Date:  2021-11-24

Review 9.  The Metabolic Features of Tumor-Associated Macrophages: Opportunities for Immunotherapy?

Authors:  Sonja S Mojsilovic; Slavko Mojsilovic; Victor H Villar; Juan F Santibanez
Journal:  Anal Cell Pathol (Amst)       Date:  2021-08-14       Impact factor: 2.916

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.